Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Arix Bioscience plc
  6. News
  7. Summary
    ARIX   GB00BD045071


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Arix Bioscience : Atox Bio Announces FDA Acceptance to File the NDA for Reltecimod to Treat Suspected Organ Dysfunction or Failure in Patients with Necrotizing Soft Tissue Infection (“Flesh-Eating Disease”)

01/06/2021 | 05:34am EDT

Atox Bio Announces FDA Acceptance to File the NDA for Reltecimod to Treat Suspected Organ Dysfunction or Failure in Patients with Necrotizing Soft Tissue Infection ("Flesh-Eating Disease")

- PDUFA Date of September 30, 2021 -

- NDA Filed Under FDA Accelerated Approval Program -

  • Necrotizing soft tissue infection (NSTI) is a rare, life-threatening disease that involves significant necrosis and tissue destruction coupled with systemic organ failure
  • If approved, reltecimod would be the first therapy to treat suspected organ dysfunction or failure in patients with NSTI

Durham, NC and Ness Ziona, Israel - December 10, 2020 - Atox Biotoday announced that the U.S. Food and Drug Administration (FDA) has accepted to file the New Drug Application (NDA) for reltecimod with a Prescription Drug User Fee Act (PDUFA) date of September 30, 2021. The proposed indication is for the treatment of suspected organ dysfunction or failure in patients ≥12 years of age with NSTI, in conjunction with surgical debridement, antibiotic therapy, and supportive care. If approved, reltecimod could advance the standard of care for patients with NSTI by providing a novel treatment option for these patients.

"The FDA's decision to file the NDA for reltecimod marks another important step forward for Atox Bio in potentially bringing this innovative therapy to patients with NSTI," said Dan Teleman, CEO of Atox Bio. "The development of reltecimod reinforces Atox Bio's expertise in immunotherapy, our deep understanding of unmet needs in the critical care setting, and commitment to improving clinical outcomes for patients affected by this rare, life-threatening disease."

Based on discussions with FDA, Atox Bio submitted an NDA under the Accelerated Approval Program. The Company believes reltecimod meets Accelerated Approval criteria as it treats a serious condition, provides meaningful therapeutic benefit over existing treatments, and demonstrates an effect on an intermediate clinical endpoint; resolution of organ dysfunction, that is reasonably likely to predict the clinical benefit of improved long-term survival.

Results from the ACCUTE study were previously announced here.

About Reltecimod

Reltecimod is a small synthetic peptide that is host-oriented and pathogen-agnostic. With its novel mechanism of action, reltecimod leads to resolution of organ dysfunction or failure by


attenuating the dysregulated immune response frequently seen in patients with NSTI. It binds to the dimer interface of CD28 expressed on T-cells, thereby modulating the acute inflammation that leads to systemic organ failure. By acting on this early step in the host immune response, reltecimod avoids the ongoing concerns about bacterial resistance and is active independent of the pathogen type.

FDA granted reltecimod Fast Track status and orphan drug designation for NSTI. The European Commission granted orphan designation for reltecimod in the treatment of NSTI.

About Necrotizing Soft Tissue Infections (NSTI)

NSTI, commonly referred to as "flesh-eating disease" or "flesh-eating bacteria" is a rare, life- threatening disease that can travel quickly from the infection site and requires frequent, rapid surgical intervention to remove dead and infected tissue to stop further progression and the need for amputation. By their nature, these surgeries often leave patients significantly disfigured. In more serious cases, acute inflammation that results from the infection leads to systemic organ dysfunction in the heart, lungs and/or kidneys. Even with the best current standard of care that includes surgical debridement, broad spectrum antibiotics, and supportive intensive care, multi- organ failure frequently occurs. Mortality rates are significant in both the short- and intermediate-term, and patients who do survive often face long and expensive hospital and rehabilitation center stays.

Hospital discharge data indicate there are approximately 30,000 cases of NSTI in the US each year, with a similar number in Europe. There are currently no therapies specifically approved for NSTI.


ACCUTE (AB103 Clinical Composite endpoint StUdy in Necrotizing Soft Tissue infEctions) was a Phase 3 randomized, placebo-controlled study that enrolled 290 patients across sites in the US and France. It evaluated the safety and efficacy of a single dose of intravenous reltecimod 0.5mg/kg versus placebo (0.9% saline) administered in conjunction with surgical debridement (removal of damaged skin, subcutaneous tissue, fascia, and sometimes muscle), antibiotic therapy, and supportive care in patients ≥12 years of age with NSTI. The trial also assessed hospital discharge status and impact on healthcare resource utilization.

About Atox Bio

Atox Bio is a late stage clinical company that develops immunotherapies for critically ill patients. The ACCUTE study was funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under Contract No. HHSO100201400013C. Major investors in the company include SR One, OrbiMed, Lundbeckfonden Ventures, Arix Bioscience plc and Adams Street Partners. The Company was established by Prof. Raymond Kaempfer and Dr. Gila Arad from the Hebrew University of Jerusalem and Yissum. Please visit www.AtoxBio.comfor more information.



Media Contact:

Julia Wilson

JW Communications juliawilsonuk@gmail.com +44 781 8430877


This is an excerpt of the original content. To continue reading it, access the original document here.


Arix Bioscience plc published this content on 11 December 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 January 2021 10:33:04 UTC

ę Publicnow 2021
09/20PRESS RELEASE : Rentschler Biopharma appoints Dr. Christian Schetter as Chief Scientific O..
09/20ARIX BIOSCIENCE PLC(LSE : ARIX) added to S&P Global BMI Index
09/03VC DAILY : Question: What Is Driving Startup -2-
09/02ARIX BIOSCIENCE : To Invest $11 Million In Disc Medicine
09/02Arix Bioscience participates in USD90 million Series B financing for Disc Medicine
09/02Disc Medicine, Inc. announced that it has received $90 million in funding from a group ..
09/01Total Voting Rights
08/31Transaction in own shares
08/16Transaction in own shares
08/16Director/PDMR Shareholding
More news
Sales 2021 0,50 M 0,68 M 0,68 M
Net income 2021 37,7 M 51,5 M 51,5 M
Net cash 2021 146 M 199 M 199 M
P/E ratio 2021 5,54x
Yield 2021 -
Capitalization 200 M 273 M 273 M
EV / Sales 2021 108x
EV / Sales 2022 88,3x
Nbr of Employees 12
Free-Float 72,2%
Duration : Period :
Arix Bioscience plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARIX BIOSCIENCE PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 3
Last Close Price 160,00 GBX
Average target price 221,50 GBX
Spread / Average Target 38,4%
EPS Revisions
Managers and Directors
Robert William Henry Lyne CEO, COO, Secretary, Director & General Counsel
Marcus Karia Group Finance Director
Peregrine D. E. M. Moncreiffe Non-Executive Chairman
Graeme Smith Chief Technology Officer
Giles Francis Bertram Kerr Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
INVESTOR AB (PUBL)30.18%68 794
HAL TRUST31.44%15 367
LIFCO AB (PUBL)58.11%13 052